Choose Your Country or Region

Buparlisib (BKM120)

Name: Buparlisib (BKM120)
Brand: Selleck Chemicals
SKU: S2247
Rating: 5 (218 reviews)

Catalog No.S2247 Synonyms: NVP-BKM120

For research use only.

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

CAS No. 944396-07-0

Selleck's Buparlisib (BKM120) has been cited by 218 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	Click to View More Targets
52 nM	116 nM	166 nM	262 nM	2.4 μM	Click to View More Targets

In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. ^[1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. ^[2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. ^[3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

glioma cell lines	M1L0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXv3bmk2PzKq		NF[1OWVKSzVyPUGtNu69VQ>?	M2nVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
U87	Mn7PRZBweHSxc3nzJGF{e2G7	M2rOflLPxE1?	MoPqO\|Jp		NVXZOVNicW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM>	M133UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
SNU-601	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\qV2N[PzKq	MVPEUXNQ	NITybndKSzVyPUCuPFE3yrFyLkC2N:69VQ>?	M2L3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-1	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXDUpA4Omh?	MXPEUXNQ	M{e1TWlEPTB;MT6wPFLDuTBwMEK4{txO	NXfDfoFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-668	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTXOms4Omh?	NXjhcoluTE2VTx?=	MVPJR\|UxRTFwNUe5xtExNjB5NN88US=>	NUH5d3lRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
AGS	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV[3Nog>	M4XiR2ROW09?	MV\JR\|UxRTFwN{G0xtExNjFzN988US=>	M3zM[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-216	NWrJTlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoHsO\|Jp	MUTEUXNQ	M2jwWWlEPTB;Mj62PVLDuTBwMEiy{txO	NXLXVHlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-5	M1fQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3;LTlczcA>?	M4XZWmROW09?	MX;JR\|UxRTFwM{WxxtExNjB7Md88US=>	M1HtelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-638	M2DtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIfwZXk4Omh?	NUnLbmoyTE2VTx?=	NI[xPHNKSzVyPUKuNlgzyrFyLkC1N:69VQ>?	Ml3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-16	NInzO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnzUO\|Jp	NV\aRol5TE2VTx?=	M1r2d2lEPTB;MT61O\|PDuTBwMECx{txO	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-484	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfTO\|Jp	MXfEUXNQ	MU\JR\|UxRTFwN{K4xtExNjB2Nd88US=>	M3HDZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-620	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlH5O\|Jp	MWXEUXNQ	M17KUGlEPTB;Mj65N\|nDuTBwMECx{txO	NEX2UFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-719	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2m2RVczcA>?	MnXQSG1UVw>?	NH;3dFRKSzVyPUOuNFM4yrFyLkCzNu69VQ>?	NHfvZ2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
MM cell lines	M2T1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYSzWoR3OTEQvF2=	M{HyZVI1cA>?	MlvRSG1UVw>?	MlH3TWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm	NUnpcpVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc1QDVpPkKyNlA4PDh3PD;hQi=>
ARP-1	M{n2V2Fxd3C2b4Ppd{BCe3OjeR?=	M1HlR\|Ex\|ryP	M2TV[lI1cA>?	MoLySG1UVw>?	M1v0Oolv\HWlZYOgUW0h[2WubDDhdI9xfG:\|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36=	M2PMU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3OFg2Lz5{MkKwO\|Q5PTxxYU6=
colon cancer cell lines	M3jj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXVNE0yOM7:TR?=	NHfXT4U4Omh?	MUPEUXNQ	NYXFbJpNUUN3ME2x{txO	M3LZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
gastric cancer cell lines	NEfMV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:wMVEx\|ryP	MnLQO\|Jp	NFvkVmdFVVOR	NITyeWFKSzVyPUKtOe69VQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HCT-116/HT-29/MKN-45	NYrxSphNSXCxcITvd4l{KEG\|c3H5	NV75c41DOs7:TR?=	MVy0PIg>		M4\5bpNpcW[2IHnuJGczKHCqYYPl	M2ixfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
HT-29 and HCT-116	M1;w[WNie3Cjc3WgZZN{[Xl?	MoDnOe69VQ>?	MlnvNlRp		NU[zU4ZNcW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5	M{LnWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
PIK3CA-mutant MCF7	M4nt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\3[o1IUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	NGruRoI4Omh?		MoPuS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1?	MoHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
PIK3CA-mutant MCF7	MYjLbY5ie2ViQYPzZZk>	NI\NdJlKSzVyPUGxOOKyO26P	NGPEVJE4Omh?		NXXteXVKUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
MCF7-myr-Akt	NYrSPGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHJS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1?	MV23Nog>		NXLQW\|F[T0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	M2PWWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWzPVY4Lz5{Mk[1N\|k3PzxxYU6=
Y1 cell line	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnKTYFGOC5zzszNM\|HPxE1?	M2jj[FI1cA>?	NX7nbI5lTE2VTx?=	NVe5cmZqcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO=	MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUK5NFQoRjJ{NkmyPVA1RC:jPh?=
human NSCLC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSwMlUuOs7:TR?=	MkDsO\|Jp		Mle1TWM2OD1zzszN	NFvFcXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke4NVM6Oyd-MkK3PFE{QTN:L3G+
human NSCLC	MWLLbY5ie2ViQYPzZZk>	MXKx{txO	NHHTXokzPGh?		NETjbGRqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70	MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN\|k{RC:jPh?=
JVM2	NHjkZXJEgXSxdH;4bYNqfHliYYPzZZk>	MWOwMlIuOjEQvF2=	M2CydFczcA>?	M1HKXWROW09?	NIXWOlBKSzVyPUCuPe69VQ>?	NEKxNpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
EHEB	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=	M{DZclAvOi1{MN88US=>	NHHueXU4Omh?	MUTEUXNQ	MV\JR\|UxRTBwN988US=>	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N\|koRjJ\|MkO4OlM6RC:jPh?=
MEC2	Mlu3R5l1d3SxeHnjbZR6KGG\|c3H5	NYnGSFVuOC5{LUKw{txO	MV[3Nog>	NG\aeJpFVVOR	NF;DdpNKSzVyPUCuO:69VQ>?	NYLLdFNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	NFvIb2tCeG:ydH;zbZMhSXO\|YYm=	M2H5VGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV?	M37ORlI1cA>?	MUfEUXNQ	M1yzbGlEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM>	M4XKN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
primary B-CLL lymphocytes	NF:wcJFMcW6jc3WgRZN{[Xl?	M{nxV2lEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV?	NV\GTWF3OjSq		M{TJOolvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO\|aX;u	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N\|koRjJ\|MkO4OlM6RC:jPh?=
SK-HEP1	NH;HdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVmxMVIx\|ryP	NYD5c5JKPzKq	Ml2xSG1UVw>?	NVrkdndNUUN3MP-8oFHPxE1?	MkjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN\|YoRjJ\|NEe5NVM3RC:jPh?=
786-0	NIjvOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTrdI5ZOS1{MN88US=>	NVHzb\|F{PzKq	NUnUTYExTE2VTx?=	NFO2V5dKSzVy78{cNe69VQ>?	MmjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN\|YoRjJ\|NEe5NVM3RC:jPh?=
human HCC cell lines	MnrFR4VtdCC4aXHibYxqfHliYYPzZZk>	MV:wMlAxPS1zzszN	MYC0PIg>		NITlO4NKSzVyPUJOwG0>	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEm5PVkoRjJ\|NEi5PVk6RC:jPh?=
Huh7	MmX0T4lv[XOnIFHzd4F6	NVjBVYxVOc7:TR?=	NXW1Ro5MPDiq		MnzNd4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0	NX7GTpFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFk6QTlpPkKzOFg6QTl7PD;hQi=>
human NSCLC cell lines	NGXzZZpCeG:ydH;zbZMhSXO\|YYm=	NEjxfogxNjF{NT20{txO	NF25cnAzPGh?	M4fl[2ROW09?	M4LpSGlEPTC\|IILhcodmeyCocn;tJFAvPC1{zszN	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkK0O\|IoRjJ\|NU[yOFczRC:jPh?=
Primary CLL cells	M{Hz[2Fxd3C2b4Ppd{BCe3OjeR?=	NWL6SYRkOS1zMN88US=>	M4DtdVQ5cA>?		MmX2bY5lfWOnczDhdI9xfG:\|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=>	M4GxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEWwPFA4Lz5{M{i1NFgxPzxxYU6=
Primary CLL cells	Mmj4T4lv[XOnIFHzd4F6	MlTWNu69VQ>?	NHrVV5U{OG2rbh?=		M{P2TYRm[3KnYYPl[EBRUTONIHHjeIl3cXS7	MlLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
Primary CLL cells	NGPNZ2FEgXSxdH;4bYMhSXO\|YYm=	MVyy{txO	NUDOPYF{OjSq		MV;pcoR2[2W\|IHPlcIwh[3m2b4TvfIlkcXS7	NHizOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
LC-1/SQSF	NWTi[HVLTnWwY4Tpc44hSXO\|YYm=	NGftdWc{\|ryP	NFmzPVYzPGh?	MUDEUXNQ	NVLtV4VX\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6MEC5N{c,OjN7OECwPVM9N2F-
BCR-ABL	NHu5[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLsd2YxNjJ3LUGw{txO	MnLrOIQ>		NHLNVWt{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NE[xNkc,OjR{NES2NVI9N2F-
T-ALL	NUDnTJBmSXCxcITvd4l{KEG\|c3H5	NG\JeGRj\XS5ZXXuJFEvPCCjbnSgOU4{KG2PIHH0JFI1cCCjbnSgNE46KGGwZDC1MlUhdU1iYYSgOFhpKGmwIHTp[oZmemWwdDDj[YxtKGyrbnW=	M2jodlI1KG:{IES4bC=>	MYLEUXNQ	MWXh[oZm[3S\|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?=	MojHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MUC3N\|YoRjJ2M{GwO\|M3RC:jPh?=
H1975	NFTMO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFi0SpExNjNvOT62{txO	NXrSVWduPzKq	MX;EUXNQ	M4jzOGlEPTB;MT6zPFXPxE1?	NF:0T2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzO\|g1Pid-MkSzN\|c5PDZ:L3G+
H1975	NWn4ZWtMSXCxcITvd4l{KEG\|c3H5	MoPHNu69VQ>?	MlrDNlRp	Mm\MSG1UVw>?	NFi0SIxqdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>?	MlPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{e4OFYoRjJ2M{O3PFQ3RC:jPh?=
BON	M2DPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jKS\|EuPc7:TR?=	M2n0XFczcA>?		NI\wdpll\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v	MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NEO1NlMoRjJ2NESzOVI{RC:jPh?=
BON	MUjBdI9xfG:\|aYOgRZN{[Xl?	M{ftOFEuPc7:TR?=	M4H5RVI1cA>?		M1roZYlv[3KnYYPld{BieG:ydH;zbZM>	NYXkV\|FLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OFM2OjNpPkK0OFQ{PTJ\|PD;hQi=>
GBM	MmjCRZBweHSxc3nzJGF{e2G7	NGjhN4Uz\|ryP	MXG0PIg>	M325VmROW09?	NE\vO\|dqdmS3Y3XkJIhq\2incjDs[ZZmdHNib3[gZZBweHSxc3nzMEBidmRiZHXjdoVie2WmIHPlcIwhfmmjYnnsbZR6	NWHsepI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFA1QTJpPkK0OVAxPDl{PD;hQi=>
FaDu	MlTUSpVv[3Srb36gRZN{[Xl?	MoTvOUDPxE1?	MoPNNlQhcA>?	M37sWmROW09?	NEHFZVFT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	NH7v[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N\|EyPDd:L3G+
EMT6	MofYSpVv[3Srb36gRZN{[Xl?	M2SwbFUh\|ryP	NGfScVIzPCCq	M2TiSWROW09?	MU\S[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	NE\hW5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N\|EyPDd:L3G+
HCT116	NYP5ZpJXTnWwY4Tpc44hSXO\|YYm=	NV\WNJlYPSEQvF2=	Mo\NNlQhcA>?	M{TWPWROW09?	NFnRXVRT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUG0O{c,OjR4M{GxOFc9N2F-
U87	M1HJcmZ2dmO2aX;uJGF{e2G7	NXzm[FBbPSEQvF2=	MX:yOEBp	M1zoZmROW09?	M{\0TXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	NIjz[YE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N\|EyPDd:L3G+
Saos-2	MU\GeY5kfGmxbjDBd5NigQ>?	MnS5OVAh\|ryP	MkHhOFghcA>?		MmfFTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>?	M4LzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
MG-63	NV;iXXRQTnWwY4Tpc44hSXO\|YYm=	NGHl[2M2OCEQvF2=	NWDOPWo{PDhiaB?=		NEXIdXRKdmirYnn0d{Bk\WyuIHnueoF{cW:w	M4j3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
SJSA-1	NHz4TFFHfW6ldHnvckBCe3OjeR?=	M3fGblUxKM7:TR?=	Mn7LOFghcA>?		MnfRTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>?	NUG2Z5JiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
Saos-2	NFrCOGlHfW6ldHnvckBCe3OjeR?=	M{Dq[\|UxKM7:TR?=	NX:4VnJrPDhiaB?=		M2\6U2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	M1P0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
MG-63	NVnNd2FwTnWwY4Tpc44hSXO\|YYm=	MUK1NEDPxE1?	NGHWb401QCCq		MV3Jcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
SJSA-1	Mn\VSpVv[3Srb36gRZN{[Xl?	NHzGbJQ2OCEQvF2=	NGW2Xm81QCCq		NXTqSohoUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
Saos-2	NGPDVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGyUo12PTBizszN	MlvwOFghcA>?		NX7BbW17UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NIPCXVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	NUG5cG16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfQOVAh\|ryP	MofUOFghcA>?		M1zqPGlvcGmkaYTzJINmdGxidnnhZoltcXS7	M1G3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
SJSA-1	NFT6bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDRO\|FlPTBizszN	MnrROFghcA>?		NEPx[pBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NUHzb\|l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
LN18	NHm4WI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Pjd\|IxKM7:TR?=	M{\uVlczKGh?	MXXEUXNQ	NX[0RXJ4UUN3MEy1JO69VQ>?	NUPFXGEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LN229	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXKc\|UzOCEQvF2=	NETHN\|E4OiCq	MlPnSG1UVw>?	MWHJR\|UxRDVizszN	MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LNZ308	NIjJTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCxbmkyOjBizszN	NHvCd2M4OiCq	M2PUWmROW09?	NFjHSmRKSzVyPEWg{txO	Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
T98G	M4TUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jvZ\|IxKM7:TR?=	NV7CWYhQPzJiaB?=	MkDVSG1UVw>?	MX7JR\|UxRDVizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
U87	M3fmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjh[24zOCEQvF2=	NF;1XI44OiCq	MkfzSG1UVw>?	NH;qV5NKSzVyPEWg{txO	M1:2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LN18	M1HKfWZ2dmO2aX;uJGF{e2G7	NInENWY2KM7:TR?=	MnfHNlQhcA>?	MW\EUXNQ	M2PUcWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	M3vmU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LNZ308	NEHUXItHfW6ldHnvckBCe3OjeR?=	NWTGRZJ3PSEQvF2=	NW[yPHY4OjRiaB?=	MmDwSG1UVw>?	M{\YXWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	NUXhS\|Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
MDA-MB-175	NEftO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO3NUDPxE1?	M2rJWlUh\A>?	M3O3[GROW09?	NXHiblhYUUN3MEyxJO69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-134	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHoUHh4OSEQvF2=	MUO1JIQ>	MnW4SG1UVw>?	NGGxTVRKSzVyPEGg{txO	NH3nUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1500	M2i1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn0OnEyKM7:TR?=	NHfIS2s2KGR?	NVHlXWhyTE2VTx?=	MlnYTWM2ODxzIN88US=>	NX\4R2YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
EFM-19	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfnbJgyKM7:TR?=	MWq1JIQ>	M1rqdmROW09?	M33Zd2lEPTB:MTFOwG0>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
ZR-75-30	NHj1TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL6VnYyKM7:TR?=	MVq1JIQ>	NGW2UJZFVVOR	NILsfGtKSzVyPEGg{txO	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-361	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrRNUDPxE1?	NGHYOlU2KGR?	NUPKbppHTE2VTx?=	Mn34TWM2ODxzIN88US=>	MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
T-47D	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxJO69VQ>?	M2nLe\|Uh\A>?	NYG5bnFDTE2VTx?=	Mmm4TWM2ODxzIN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
SK-BR-3	NGPGXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPKUmYyKM7:TR?=	M1yyfVUh\A>?	NEfTTW1FVVOR	MVPJR\|UxRDFizszN	MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
UACC-732	NV7zd2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DOZVEh\|ryP	MmS4OUBl	NYewb5ZtTE2VTx?=	MWPJR\|UxRDFizszN	NVH2e5RGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-474	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDPelNZOSEQvF2=	MYO1JIQ>	MkjCSG1UVw>?	MV;JR\|UxRDFizszN	NEjpXFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC202	NY\FVnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvINUDPxE1?	MlLrOUBl	MUfEUXNQ	MVLJR\|UxRDFizszN	NIXWVGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MCF7	NInvdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzkV5E{OSEQvF2=	MXe1JIQ>	NUDkXmVbTE2VTx?=	M1uzTmlEPTB:MTFOwG0>	M4DzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-415	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLUNUDPxE1?	MkjBOUBl	MYDEUXNQ	MVXJR\|UxRDFizszN	NYToUYlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-453	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLQN\|gyKM7:TR?=	NVe2UpdkPSCm	MU\EUXNQ	M4PXTmlEPTB:MTFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
ZR-75-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrMVZcyKM7:TR?=	NYPQV\|ZbPSCm	MofrSG1UVw>?	NV76XYtQUUN3MEyxJO69VQ>?	NEPkZ\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC38	NY\yZYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2xJO69VQ>?	MWK1JIQ>	NVfGXnNSTE2VTx?=	NIjIVnFKSzVyPEGg{txO	NWD1cZZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1419	NWq4fJJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi1[YNtOSEQvF2=	NF70XYc2KGR?	M4C3cWROW09?	NGPxeo1KSzVyPEGg{txO	MnnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
UACC-812	M{Hrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny4NUDPxE1?	NYf4RXZqPSCm	MnTwSG1UVw>?	NI[5VmVKSzVyPEGg{txO	NH7ublM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1187	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUe0UIVCOSEQvF2=	NU\YOFlPPSCm	M4LXW2ROW09?	NGL1SphKSzVyPEGg{txO	MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
KPL-1	NYPW[mp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIr0bmsyKM7:TR?=	MnXLOUBl	NEX1NolFVVOR	M4jmSGlEPTB:MTFOwG0>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
SUM-225	M13lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfWNUDPxE1?	NX3OTmRqPSCm	MWLEUXNQ	MoL6TWM2ODxzIN88US=>	M1zCNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
EFM-192A	M16yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDPNUDPxE1?	MlyyOUBl	NHXsRodFVVOR	MVTJR\|UxRDFizszN	Mo\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
JIMT-1	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnMNUDPxE1?	NWrwUoRHPSCm	MVfEUXNQ	MVjJR\|UxRDFizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1143	NYrzN4QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHPeWMxOSEQvF2=	NHfIV\|g2KGR?	NXPrRo5ITE2VTx?=	NEXRRZlKSzVyPEGg{txO	NX;0OnlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC2218	NHmzVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LQNVEh\|ryP	MmLpOUBl	M1n5RWROW09?	MWrJR\|UxRDFizszN	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-468	NFXSOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e2eVEh\|ryP	Mk\NOUBl	M4DwSmROW09?	M3LlbWlEPTB:MTFOwG0>	NW\5ZoZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-20	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLrNUDPxE1?	NGL6N3I2KGR?	NWnBZXAzTE2VTx?=	MUPJR\|UxRDFizszN	NV;wN5NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-435	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jWdFEh\|ryP	MVu1JIQ>	NXrrNWU1TE2VTx?=	MnP4TWM2ODxzIN88US=>	MoP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
BT-549	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzRNUDPxE1?	MnT2OUBl	MkfWSG1UVw>?	M4r2XGlEPTB:MTFOwG0>	M{K2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC1806	NUXwNGtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vzTVEh\|ryP	M3X4dVUh\A>?	NWLNRZRLTE2VTx?=	M1rKcWlEPTB:MTFOwG0>	M1zG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC1937	M1TxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnGUW1vOSEQvF2=	M3rweVUh\A>?	M3fWbmROW09?	NGCyNFlKSzVyPEGg{txO	M1vKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
Hs578T	M4nuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSxJO69VQ>?	MXS1JIQ>	NFWwdI5FVVOR	MlzSTWM2ODxzIN88US=>	M3fiWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MCF7	MV;DfZRwfG:6aXOgRZN{[Xl?		MkSzO\|IhcA>?	MlXWSG1UVw>?	NYnmWmNVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=>	NGjHdZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
DU145	MojuR5l1d3SxeHnjJGF{e2G7		M{K0ZlczKGh?	NI\SXoVFVVOR	NFf3NplEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
A2780	NF\CWHJEgXSxdH;4bYMhSXO\|YYm=		NFGxRVk4OiCq	M1\6T2ROW09?	NIfaZ5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN	M3PUb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
U87MG	M2THdmN6fG:2b4jpZ{BCe3OjeR?=		NIL3d2g4OiCq	MljaSG1UVw>?	MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh\|ryP	MmTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	MkXnSpVv[3Srb36gRZN{[Xl?		M1TwT\|EhcA>?	NHnqUYhFVVOR	MlfOTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1?	NGeyU3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
DU145	NEW0O\|NHfW6ldHnvckBCe3OjeR?=		NUXpd4FOOSCq	MnvNSG1UVw>?	MXLJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
A2780	M4C1[GZ2dmO2aX;uJGF{e2G7		MUixJIg>	MXjEUXNQ	M4rK[GlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	NHHEO5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
MCF7	MnPxSpVv[3Srb36gRZN{[Xl?		MlroNUBp	Ml3JSG1UVw>?	MULJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
U87MG	MWHGeY5kfGmxbjDBd5NigQ>?		M37Mb\|EhcA>?	NGXwU4xFVVOR	NHLDUFhKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR\|UxKG:oIECuNVMh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
A2780	NYDORXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjzO\|IhcA>?	NEnqcFRFVVOR	M3zGUWVEPTB;MD61NkDPxE1?	NGTXSZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
Huh7	MlvrSpVv[3Srb36gRZN{[Xl?	M2n2NFEh\|ryP	MXqxJIg>	NYe3Z2M1TE2VTx?=	Mo\GTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR?	NXq0OGd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFQ1ODNpPkK1NFA1PDB\|PD;hQi=>
BNL	M4rKOWZ2dmO2aX;uJGF{e2G7	M1f2TVEh\|ryP	MmPWNUBp	NEOxVIxFVVOR	MWnJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gV\|Y>	NWDXPXZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFQ1ODNpPkK1NFA1PDB\|PD;hQi=>
BON-1	NIXPOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jBV\|UxOCCwTR?=	MYWxNEBl	NH\XPVZFVVOR	MlPOTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NGPodHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
BON-1	MlnYSpVv[3Srb36gRZN{[Xl?	MVe1NFAhdk1?	M1G3[\|QhcA>?	M{PqRWROW09?	MX3Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd\|	MliwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
QGP-1	MWTGeY5kfGmxbjDBd5NigQ>?	MWS1NFAhdk1?	MoL6OEBp	M2m3fWROW09?	M3\JOWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O=	NGnhOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
HCT-15	MkDMRZBwfG:\|aYOgRZN{[Xl?	M{H6NlExKM7:TR?=	NIDuSJg1QCCq	M{fmVWROW09?	Ml3NTY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUG1JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	NXnw[VljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
HCT-116	M4nh[GFxd3Sxc3nzJGF{e2G7	M4\CTlExKM7:TR?=	NGPwTo41QCCq	MYrEUXNQ	MofCTY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NEXuSYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
NCI-H460	MkHuRZBwfG:\|aYOgRZN{[Xl?	MVexNEDPxE1?	MXe0PEBp	MoHDSG1UVw>?	NV7OPYozUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=>	MljGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
SKOV-3	NIj5ZWpCeG:2b4Ppd{BCe3OjeR?=	MVexNEDPxE1?	NG[1dFE1QCCq	MYfEUXNQ	MoXmTY5lfWOnczDhdI9xfG:\|aYOgbY4hW0uRVj2zJINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
BSY-1	M3zrfWFxd3Sxc3nzJGF{e2G7	NF\xVm8yOCEQvF2=	NUXzZph1PDhiaB?=	NXXzd\|R4TE2VTx?=	MXzJcoR2[2W\|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	M{nPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-1	MknsRZBwfG:\|aYOgRZN{[Xl?	Ml3WNVAh\|ryP	MoHPOFghcA>?	M3Hib2ROW09?	MYnJcoR2[2W\|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	NIG1eYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
NCI-H522	NULJNHFwSXCxdH;zbZMhSXO\|YYm=	NF73XIwyOCEQvF2=	M1\Ec\|Q5KGh?	M2j3ZWROW09?	MVzJcoR2[2W\|IHHwc5B1d3Orcx?=	NVn5TnZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
OVCAR-3	MoTxRZBwfG:\|aYOgRZN{[Xl?	MUGxNEDPxE1?	MVO0PEBp	NXf2XoJZTE2VTx?=	MVnJcoR2[2W\|IHHwc5B1d3Orcx?=	M3TrSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
HBC-5	Mn7rRZBwfG:\|aYOgRZN{[Xl?	M3u4VlExKM7:TR?=	Mn;VOFghcA>?	NYHob4oxTE2VTx?=	MULJcoR2[2W\|IHHwc5B1d3Orcx?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
RXF-631L	MlmwRZBwfG:\|aYOgRZN{[Xl?	MnXrNVAh\|ryP	MVO0PEBp	MknJSG1UVw>?	M2KzUWlv\HWlZYOgZZBweHSxc3nz	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
MKN-45	NHLjfGlCeG:2b4Ppd{BCe3OjeR?=	NVfx[HU1OTBizszN	NInFSHA1QCCq	NV7HR\|FlTE2VTx?=	NEK5XZVKdmS3Y3XzJIFxd3C2b4Ppdy=>	M2LZUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
LNCaP	NXzGeYdxTnWwY4Tpc44hSXO\|YYm=	M1HkN\|Eh\|ryP			NIKw[XdUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?=	M2LnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO\|k6Lz5{NUO2NFc6QTxxYU6=
LNCaP95	M3zyOmZ2dmO2aX;uJGF{e2G7	M2nBcFEh\|ryP			M4HJcHN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	M3XMUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO\|k6Lz5{NUO2NFc6QTxxYU6=
A549	NELKWoVHfW6ldHnvckBCe3OjeR?=	M{PHZ\|UxOCCwTR?=	NXOxUnhuPDhiaB?=	NUn5fYlpTE2VTx?=	M2C4dGlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w	NW\ISYc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|czQTlpPkK1PVM4Ojl7PD;hQi=>
A549	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP1V5QyKM7:TR?=	NH63eXU4OiCq	MXHEUXNQ	NF76SJRKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NIjwemU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzO\|I6QSd-MkW5N\|czQTl:L3G+
H522	NXfVdo5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP5fWNbOSEQvF2=	M1ex[lczKGh?	MoD4SG1UVw>?	NF[4S2ZKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M1\5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO\|I6QTxxYU6=
SKMES-1	M3TKOGN6fG:2b4jpZ{BCe3OjeR?=	NXu1dJVQOSEQvF2=	Mo\0O\|IhcA>?		NHfHW5BKdmS3Y3XzJINmdGxiZHXheIg>	MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
H596	MYXGeY5kfGmxbjDBd5NigQ>?	MVqxJO69VQ>?			NH3TUYxKdXCjaYLzJINmdGxibXnndoF1cW:w	MkHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
HCC2450	MWHGeY5kfGmxbjDBd5NigQ>?	M4nVOlEh\|ryP			Mk\STY1x[Wm{czDj[YxtKGmwdnHzbY9v	M4r3U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEGzN\|E5Lz5{NkCxN\|MyQDxxYU6=
HCT116	NGjU[YxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoPSO\|IhcHK\|		Ml7pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFgh\|ryPLh?=	MlLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
MCF7	NHu0UJdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHK0d\|Q4OiCqcoO=		NHL0SFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGg{txONg>?	NHnvZ209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
U87MG	Ml3vRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGf4cYY4OiCqcoO=		MkjPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOEfNS{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT62OEDPxE1w	M{H0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
A549	NWLhNYdSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MY[3NkBpenN?		MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwMEeg{txONg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
HeLa	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGrGNHk4OiCqcoO=		M1T0OWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND6zOEDPxE1w	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
HCT116	MYfGeY5kfGmxbjDhd5NigQ>?	NInlVGYyOCC3TR?=	NGW2UJYyKGi{		M{LKSGlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KEGtdDDwbI9{eGixconsZZRqd25iYYSgNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NEP1TVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma	NXPUNXRRS2WubDDjfYNt\SCjc4PhfS=>	M1uyUlUhfU1?	M37sUVI1KGi{cx?=		NYj1SmRyS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTJyNUigcYVt[W6xbXGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGP1ZmcyKHCqYYPlJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrcx?=	NVfMXYZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
A2058 melanoma	NH;4bGRE\WyuIHP5Z4xmKGG\|c3H5	NY\XXYdOPSC3TR?=	NHO2R3UzPCCqcoO=		NFvKU2VE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjB3ODDt[Yxidm:vYTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	NWLqdmJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
SKOV3	MljZR4VtdCCleXPs[UBie3OjeR?=	M2n6fFIhfU1?	MnriNlQhcHK\|		MXTD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDTT29XOyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDCyJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM>	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
SKOV3	NXHm[2NvS2WubDDjfYNt\SCjc4PhfS=>	NWDDR25SOiC3TR?=	NUO1WoJZOjRiaILz		MVHD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDTT29XOyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhW3WkR{GgdIhie2ViYYSgNkB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{	M3nDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
MDA-MB-231	NHfieo9EgXSxdH;4bYNqfHliYYPzZZk>		M1TXUFczKGi{cx?=		NYTJTZpyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU45QCEQvF2u	NFrDdYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO\|QzQSd-MkmxNFc1Ojl:L3G+
PC3	NXrzZY9JS3m2b4TvfIlkcXS7IHHzd4F6		NGPSSGI4OiCqcoO=		NGfibYxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvOzRizszNMi=>	M3rVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
T47D	NYPzO282S3m2b4TvfIlkcXS7IHHzd4F6		MlG2O\|IhcHK\|		NYm3OnJiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPi57MjFOwG0v	NUTjWm8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFc1OjlpPkK5NVA4PDJ7PD;hQi=>
MCF7	NY\ufI9xS3m2b4TvfIlkcXS7IHHzd4F6		MmnQO\|IhcHK\|		NVTGVHhwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTFwMEWg{txONg>?	NG\QVIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO\|QzQSd-MkmxNFc1Ojl:L3G+
TC32	M1XmcpFJXFNiYYPzZZk>				MojCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NXS1[\|VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MlTydWhVWyCjc4PhfS=>				Mk\2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NH7pXIhyUFSVIHHzd4F6				M3nqPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NUDtWpl[eUiWUzDhd5NigQ>?				MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NHvYfYZyUFSVIHHzd4F6				NYmxVYJseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M4HQdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MVXxTHRUKGG\|c3H5				NV7HUm4zeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NH:wUYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NVL6bpU6eUiWUzDhd5NigQ>?				NEPUWVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	M2PmUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MlTpdWhVWyCjc4PhfS=>				NWT4WIFZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NWjvNHBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NV36O4VjeUiWUzDhd5NigQ>?				Mnr0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NUPYZYlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MoLwdWhVWyCjc4PhfS=>				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NYfWRoxzeUiWUzDhd5NigQ>?				M2jkRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NWHOOJpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NVW2R2N5eUiWUzDhd5NigQ>?				M{\ZXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	M1TnZ5FJXFNiYYPzZZk>				NG\vWnNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NEHnN4dyUFSVIHHzd4F6				NWHCR3U4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	M2q4PJFJXFNiYYPzZZk>				M2\SVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	M2f0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NXTSbVZ6eUiWUzDhd5NigQ>?				NH3ueFVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MnTNdWhVWyCjc4PhfS=>				MmfFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NFTNRpNyUFSVIHHzd4F6				MorLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M2Xtc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MWfxTHRUKGG\|c3H5				M17sO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MWDxTHRUKGG\|c3H5				NIG2SmpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	M{TqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NVvwPIRSeUiWUzDhd5NigQ>?				M3TBOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NInnSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NH[3TWlyUFSVIHHzd4F6				MkjOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NVTPcI55eUiWUzDhd5NigQ>?				M3XjTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	M2O1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MW\xTHRUKGG\|c3H5				NF3DWmJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	M3XzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	M1n0U5FJXFNiYYPzZZk>				NXLUZ3JmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	Mmm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M4jSVpFJXFNiYYPzZZk>				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	M37IZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NV[3fGlreUiWUzDhd5NigQ>?				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
insect	NHjYRpZHfW6ldHnvckBie3OjeR?=				MmTVTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKaYOteIFo\2WmIIC4OYFteGijL4CxNVBidHCqYTDFOVQ2UyCvdYThcpQh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODFzIN88UU4>	Mo\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
insect	NGLJTWdHfW6ldHnvckBie3OjeR?=				NXPTbHI4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDIbZMufGGpZ3XkJJA5PWGucHjhM5AyOTCjbIDoZUBGPTR{SzDteZRidnRiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyxiSVO1NEA:KDBwMEK5JO69VS5?	Mn64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
Sf21	NXnQdmx7TnWwY4Tpc44h[XO\|YYm=		NGn2bogyKGi{		M3rMRWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCyMUGw[IVtfGFxcnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFEhcHJiYomgRYxmgGF4M{OgWJJi[2W{LXLhd4VlKG[udX;y[ZNk\W6lZTDwc4xieixiSVO1NEA:KDBwMUK1JO69VS5?	NVzMN3NCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
MCF7	NVPoTnJbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2ToVVczKGi{cx?=		MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiaHHyZo9zcW6pIGDJT\|NESSCHNUS1T{BufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNlA3KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|NE[wO{c,OzByM{S2NFc9N2F-
Sf21	NVjCTIlrTnWwY4Tpc44h[XO\|YYm=		MVKxJIhz		M1Lx[mlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCyMUGwZoV1[S:{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDwPFVidHCqYTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBqdnOnY4SgZ4VtdHNidYPpcochWEmSMjDhd{B{fWK\|dILheIUhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDBcIV5[TZ\|MzDUdoFk\XJvYnHz[YQh\my3b4Lld4NmdmOnIIDvcIFzcSxiSVO1NEA:KDBwMkO0JO69VS5?	M1LOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
T47D	NYP2R4JGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGH2fFg4OiCqcoO=		MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR2N1SgZ4VtdHNiaHHyZo9zcW6pIGDJN2tESSCKMUC0O3IhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlI5PiEQvF2u	NH7qPI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
PC3	MnizSpVv[3Srb36gZZN{[Xl?		NVTrcZJNOiCqcoO=		M4L4OmlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KG2nYYP1doVlKGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOzZ3IN88UU4>	NFuwWok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
HT-29	NGW4V3NE\WyuIHP5Z4xmKGG\|c3H5	M1nNOFAvOTFzIITvJFMhfU1?	M{DadVI1KGi{cx?=		MlzNR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTHQuOjliY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNE4yOTFidH:gN{B2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	M3fS[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
A2058	MmfkSpVv[3Srb36gZZN{[Xl?		MnvVNUBpeg>?		NXKzOY9xUW6qaXLpeIlwdiCxZjDUU3JEOiCrbjDoeY1idiCDMkC1PEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCSS1KvRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYK0O\|Mh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMtKEmFNUCgQUAxNjRzNjFOwG0v	M1TaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=
A2058	MnfwSpVv[3Srb36gZZN{[Xl?		M1TDWlEhcHJ?		M3O4emlvcGmkaYTpc44hd2ZiVF;SR\|EhcW5iaIXtZY4hSTJyNUigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hWzZicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlI{PS9{M{[gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlU2OyEQvF2u	M2DGR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-AKT (T308) / p-AKT (S473) / AKT ; p-FOXO3a (S253) / FOXO3a ; Nuclear NF-κB p65 / NF-κB p65 ; p-ERK / ERK / LC3 ; p-STAT3 / STAT3 / p-ERK / ERK / p-S6 ; p-MET / MET	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a	28036259
Growth inhibition assay	Cell viability	26673665

In vivo

BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. ^[1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. ^[2]

Protocol (from reference)

Kinase Assay:^[1]	PI3K biochemical assay (ATP depletion assay): BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:^[1]	Cell lines: A2780 cells. Concentrations: 0-6.6 μM Incubation Time: 3 days. Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 10³ cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux. (Only for Reference)
Animal Research:^[1]	Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice. Dosages: ~60 mg/kg. Administration: Dosed orally daily (q.d.). (Only for Reference)

References

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

+ Expand

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	410.39
Formula	C₁₈H₂₁F₃N₆O₂
CAS No.	944396-07-0
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

Download Buparlisib (BKM120) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	December 12 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):